Back to results
US 11,884,740 B1Granted
Anti-CD20 antibody compositions
AssigneesTG Therapeutics, Inc., Laboratoire Francais Du Fractionnement Et Des Biotechnologies
InventorsGeorge Costas Avgerinos, Patrick Michael Hossler, Jill A. Myers, Yune Z. Kunes
Life of this patent
Estimating the term…
Abstract
Provided herein are populations of anti-CD20 antibody proteins with specified ranges of post-translational modifications. Also provided are methods of using and methods of making such populations of anti-CD20 antibody proteins.
Claims15
A composition comprising a population of anti-CD20 antibody proteins, wherein the anti-CD20 antibody proteins in the population are expressed from one or more nucleic acid sequences encoding a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 1 and a light chain comprising the amino acid sequence of SEQ ID NO:
- 2, and wherein the population of anti-CD20 antibody proteins has an N-glycan profile comprising 10 to 20% galactosylated glycans and 20 to 40% fucosylated glycans.
Dependencies are inferred from the claim text.